MATERIAL SAFETY DATA SHEET
Product Name : BRAVECTO Chewable Tablets for Dogs
MATERIAL SAFETY DATA SHEET
Version 1 issued : February , 2015 Page : 2 of 11
Major Health Hazards : No significant risk factors have been found for this product .
Potential Health Effects
BRAVECTO Fluralaner Chewable Tablets for Dogs ( Fluralaner 13.64 % w / w ) have low oral and dermal toxicity . In vitro binding specificity studies indicate that fluralaner has little specificity for GABA ligand-gated chloride in mammals , with a high affinity for arthropod receptors . Fluralaner is for veterinary use only and is not present in any products registered for human use . The main route of exposure is accidental or deliberate ingestion . Product is supplied in a child resistant pack . Opportunities for exposure to the product are further reduced due to BRAVECTO ’ s long action (> 3 months against fleas and > 4 months against paralysis ticks ) - pets are likely to be dosed with BRAVECTO a maximum of 4 times per year .
Inhalation : Being an unscored tablet that is administered to dogs whole and not broken , the product is unlikely to pose an acute inhalation toxicity risk .
Short Term Exposure : No data . Long Term Exposure : No data .
Skin Contact : Short Term Exposure : Available data indicates that this product has low dermal toxicity . Slight potential for skin irritation . No skin sensitization potential .
Long Term Exposure : No data for health effects associated with long term skin exposure . Eye Contact : Short Term Exposure : This product may be slightly irritating to eyes , but being an unscored tablet that is typically administered whole , this route of exposure is unlikely during normal use .
Long Term Exposure : No data for health effects associated with long term eye exposure .
Ingestion : Short Term Exposure : Significant oral exposure is considered to be unlikely during normal use of the product . No adverse effects are expected from accidental ingestion of BRAVECTO tablet ( s ). Individual ( child resistant ) blister packaging limits access to more than one tablet at once . If any symptoms develop or if feeling unwell , seek medical advice immediately .
Long Term Exposure : In a 90 day study of fluralaner in rats , the NOAEL was established orally at the highest dose of 400 mg / kg / body weight / day . The liver is the main elimination organ of fluralaner and a sensitive target for effects as reflected by increased liver enzyme activity in blood plasma with decreased lipid and protein concentration , increased organ weight and increased hepatocellular fatty change . In the absence of any indicator of liver injury , these changes are considered to represent reversible metabolic effects .
Carcinogen Status : SWA : No significant ingredient is classified as carcinogenic by SWA . NTP : No significant ingredient is classified as carcinogenic by NTP . IARC : No significant ingredient is classified as carcinogenic by IARC .
MATERIAL SAFETY DATA SHEET Issued by : Intervet Australia Pty Limited ( trading as MSD Animal Health ) Phone : 1 800 033 461 ( Business Hours ) Poisons Information Centre : 13 11 26 from anywhere in Australia , ( 0800 764 766 in New Zealand )